Skip to content

To compare the effectiveness of homoeopathic remedy in centesimal potency and 50 millesimal potency for irritable bowel syndrome.

Comparative effectiveness of individualised homoeopathic medicines in lm potencies and centesimal potencies for the management of irritable bowel syndrome: a prospective randomized clinical study - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/06/069214
Enrollment
84
Registered
2024-06-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K58- Irritable bowel syndrome

Interventions

Intervention1: LM potency will be given: after proper case-taking and forming the totality individualised homoeopathy medicine will be given in LM potency Control Intervention1: Centesimal potency wil

Sponsors

National Institute of Homoeopathy
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a. Patients suffering from IBS as per Rome IV diagnostic criteria b. Both sexes c. Age 18-65 years d. Patients willing to participate in the study and giving written informed consent. e. Ability to Understand Bengali or Hindi or English

Exclusion criteria

Exclusion criteria: a. Any major gastrointestinal surgery in the last 6 months b. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life threatening illness affecting the quality of life or any organ failure. c. Currently receiving standard therapy for IBS and/ or homoeopathic treatment for any chronic condition(s) d. Pregnant and lactating women e. Self-reported immune compromised conditions f. Substance abuse and/or dependence g. Patients who are too sick for consultation

Design outcomes

Primary

MeasureTime frame
Assessment of increase or decrease in IBS-QOL questionnaire total score in patient suffering from Irritable Bowel Syndrome Timepoint: Baseline and every month up to 6 months of treatment.

Secondary

MeasureTime frame
Assessment of increase or decrease in IBS-SSS questionnaire total score in patient suffering from Irritable Bowel Syndrome Timepoint: Baseline and every month up to 6 months of treatment.

Countries

India

Contacts

Public ContactDr Gobind Narayan Gupta

National Institute of Homoeopathy

dr.gn05gupta@gmail.com9163197805

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026